Studies that evaluated the use of stem cell therapies in COPD with published results

Registry codeEnrolment (S/C)Patient conditionsIntervention (cell source)Cell dosageDelivery routeMain outcomesRef.
NCT011102524/4Severe COPDAutologous BMMCs1×108 cells·mL−1IntravenousAutologous cell therapy for COPD patients is a safe procedure and free of adverse effects[5, 64]
NCT0068372262/46Moderate-to-severe COPDAllogenic MSCs1×108 cells per infusion (2×106 cells·min−1)IntravenousNo infusion toxicities, deaths or adverse effects were observed
Systemic MSC administration appears to be safe
NCT0130651310/7Severe emphysemaAutologous MSCs1–2×106 cells·kg−1IntravenousProcedure is safe and free of adverse effects[67]
NCT0401872910/10Severe COPDAllogenic BM-MSCs1×108 cells per 30 mL (2×107 cells·min−1)IntrabronchialNo administration-related toxicities were observed, nor serious adverse effects or death[68]
ACT126140007316959/9Mild-to-very severe COPDAllogenic BM-MSCs2×106 cells·kg−1IntravenousMSC infusion showed no attributable adverse side-effects and was well tolerated[70]
ISRCTN7044393820/20Moderate-to-severe COPDAllogenic UC-MSCs1.5×106 cells·kg−1IntravenousNo infusion-related toxicities, death or severe adverse events were observed[71]
NCT0241233220/20Moderate-to-severe COPDAutologous BMMCs and/or AD-MSCs1×108 cells per infusion (single infusion); 5×107 cells per infusion (co-infusion)IntravenousCo-infusion of BMMCs and AD-MSCs is a safe procedure[74]
NCT0443310440/–Allogenic UC-MSCs1×106 cells·kg−1IntravenousStudy is not yet complete[73]

The cell-based therapy methodologies for each clinical trial mentioned in this table are represented in figure 3. ACT: Australian Clinical Trial (; AD-MSC: adipose tissue-derived mesenchymal stem cell; BM-MSC: bone marrow-derived mesenchymal stem/stromal cell; BMMC: bone marrow mononuclear cell; ISRCTN: International Standard Registered Clinical Trial Number (; MSC: mesenchymal stem/stromal cell; NCT: National Clinical Trial (; S/C: started/completed; UC-MSC: umbilical cord-derived mesenchymal stem cell.